Photo by bigdodzy from unsplash
Idiopathic central precocious puberty (iCPP) is common in paediatric endocrinology. Gonadotropin‐releasing hormone agonists (GnRHa) are safe, but the effect on final height and the ideal timing for treatment remains controversial.… Click to show full abstract
Idiopathic central precocious puberty (iCPP) is common in paediatric endocrinology. Gonadotropin‐releasing hormone agonists (GnRHa) are safe, but the effect on final height and the ideal timing for treatment remains controversial. This study aims to assess the effectiveness of GnRHa on growth outcomes in girls with iCPP treated before and after the age of 8 years old.
Keywords:
height benefit;
precocious puberty;
central precocious;
endocrinology;
age
Journal Title: Clinical Endocrinology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Endocrinology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!